Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

DBV Technologies S.A. (DBV.F)

Compare
1.2520
+0.0220
+(1.79%)
At close: April 17 at 9:17:15 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DBV.F

Recent News: DBV.F

View More
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
GlobeNewswire 6 days ago
Novo gains Lexicon obesity drug; CRISPR COO to step down

Novo gains Lexicon obesity drug; CRISPR COO to step down
BioPharma Dive 21 days ago
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
GlobeNewswire 21 days ago
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
GlobeNewswire 25 days ago
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
GlobeNewswire last month
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
GlobeNewswire 3 months ago
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
GlobeNewswire 3 months ago
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
Benzinga 4 months ago
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
GlobeNewswire 4 months ago
Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024
GlobeNewswire 4 months ago
DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change
GlobeNewswire 5 months ago
View More

Related Tickers

BT3.BE Lineage Cell Therapeutics Inc
0.3600
-1.10%
 
HQ1.MU Oruka Therapeutics Inc. R
7.50
+2.04%
 
MVR0.BE Medivir AB
0.1372
-2.42%
 
05Y.MU Vivoryon Therapeutics NV
1.7140
0.00%
 
PROT Proteonomix, Inc.
0.0000
0.00%
 
HTD.MU Corcept Therapeutics Inc
57.90
-3.60%
 
ICY.HA Incyte Corp
51.16
-0.31%
 
W1H.F Onco-Innovations Limited
1.0200
-2.86%
 
RASP Actavia Life Sciences, Inc.
0.0040
0.00%
 
MVR0.F Medivir AB (publ)
0.1458
-1.88%